July 12, 2016

Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward

Key Points

Key points are not available for this paper at this time.

Abstract

The EFS was uniformly poor for children with recurrent/refractory osteosarcoma in these single-arm phase II trials. We have now constructed baseline EFS outcomes that can be used as a comparison for future phase II trials for recurrent osteosarcoma.

AI에게 질문

Bookmark

Cite This Study

Lagmay et al. (Tue,) studied this question.

synapsesocial.com/papers/69d831b361e2ce1627d18e4a https://doi.org/https://doi.org/10.1200/jco.2015.65.5381

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Second and Subsequent Recurrences of Osteosarcoma: Presentation, Treatment, and Outcomes of 249 Consecutive Cooperative Osteosarcoma Study Group Patients2008 · 235 citations
2Assessment of tumour response to chemotherapy for metastatic colorectal cancer: accuracy of the RECIST criteria2002 · 75 citations
3Nonparametric Estimation from Incomplete Observations1958 · 39,094 citations
4A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A Children's Oncology Group study2007 · 209 citations
5A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: A Children's Oncology Group study2007 · 28 citations

AI에게 질문

Bookmark